-- 週四,歐洲天然氣期貨價格上漲,此前有報導稱,美國和伊朗正在考慮將目前的停火協議延長兩週,以便有更多時間進行和平談判。 荷蘭TTF近月合約上漲1.96%,至每兆瓦時42.21歐元(49.72美元);英國NBP期貨上漲1.91%,至每熱量單位105.65便士(1.42美元)。 根據彭博社引述一位知情人士的消息報道,原定於下週二結束的停火協議可能會進一步延長,因為雙方談判代表計劃舉行技術性會談,內容包括重新開放霍爾木茲海峽以及伊朗的核濃縮問題。 同時,美國中央司令部公佈了美國海軍艦艇執行對伊朗封鎖的錄音,錄音顯示,往返伊朗港口的商船將面臨「攔截和扣押」的威脅。 然而,根據霍爾木茲海峽監測機構的數據,在過去24小時內,通過該海峽的船隻數量略有增加,共有19艘。 根據英國聯合海事資訊中心的數據,這一數字仍遠低於每天138艘的典型日均通行量。 因此,澳新銀行高級大宗商品策略師丹尼爾·海恩斯指出,儘管人們對達成潛在和平協議的樂觀情緒日益高漲,但交易員們仍然意識到,由於海峽實際上仍然處於關閉狀態,「供應仍然嚴重受限」。 他將近期能源價格的回檔歸因於「投資基金近期累積的大量淨多頭部位」的平倉。 據歐洲天然氣基礎設施協會稱,歐洲天然氣庫存持續淨成長,庫存量仍低於去年同期的 35.97%,目前庫存量佔產能的 29.55%。
Related Articles
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.